Discover open access scientific publications

Search, annotate, share and cite publications

Publications by John M. Kirkwood

An Interferon-Driven Oxysterol-Based Defense Against Tumor-Derived Extracellular Vesicles

Cancer Cell

English

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Journal of Clinical Oncology

English

E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 Mg/Kg Alone or in Combination With High Dose Interferon-Α2b in Advanced Melanoma

Clinical Cancer Research

Cancer Research

Oncology

2018

English

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement

Journal for ImmunoTherapy of Cancer

English

An Update on the Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma: Version 2.0

Journal for ImmunoTherapy of Cancer

English

NCI 8628: A Randomized Phase 2 Study of Ziv-Aflibercept and High-Dose Interleukin 2 or High-Dose Interleukin 2 Alone for Inoperable Stage III or IV Melanoma

English

Chemoprevention Agents for Melanoma: A Path Forward Into Phase 3 Clinical Trials

English

Function but Not Phenotype of Melanoma Peptide-Specific CD8+ T Cells Correlate With Survival in a Multiepitope Peptide Vaccine Trial (ECOG 1696)

International Journal of Cancer

Cancer Research

Oncology

2012

English

Melanoma Brain Metastases: An Unmet Challenge in the Era of Active Therapy

Current Oncology Reports

Oncology

2013

English

Erratum To: Progression of Cutaneous Melanoma: Implications for Treatment

Clinical and Experimental Metastasis

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by John M. Kirkwood

An Interferon-Driven Oxysterol-Based Defense Against Tumor-Derived Extracellular Vesicles

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 Mg/Kg Alone or in Combination With High Dose Interferon-Α2b in Advanced Melanoma

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement

An Update on the Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma: Version 2.0

NCI 8628: A Randomized Phase 2 Study of Ziv-Aflibercept and High-Dose Interleukin 2 or High-Dose Interleukin 2 Alone for Inoperable Stage III or IV Melanoma

Chemoprevention Agents for Melanoma: A Path Forward Into Phase 3 Clinical Trials

Function but Not Phenotype of Melanoma Peptide-Specific CD8+ T Cells Correlate With Survival in a Multiepitope Peptide Vaccine Trial (ECOG 1696)

Melanoma Brain Metastases: An Unmet Challenge in the Era of Active Therapy

Erratum To: Progression of Cutaneous Melanoma: Implications for Treatment